SAN DIEGO, Feb. 3, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA) is pleased to announce the results for its quarter ending December 31, 2011. The company's revenue increased in excess of 115% over the prior quarter from $198,812.60 to $430,139.36. Since the close of the first quarter 2011, to the close of the fourth quarter 2011, company revenues have increased an accumulative 3941%, and quarter over quarter since the first quarter 2011 have had a compounded quarterly increase of 101%. This increase comes from its subsidiary Wellness Managed Services, which engages in the management and development of Health and Wellness facilities and hydroponics stores throughout North America.

"We are very pleased with our year end results; we have had new management in place for just over eight months and have seen very strong growth. However, we did have some setbacks at the beginning of the third quarter and we were able to resolve those at the end of the fourth quarter. We anticipate having significant growth throughout 2012 with the development of Wellness Managed Services as well as the commercialization of our much anticipated Hemp Compounds business, which has focused on the research, development and sales of hemp extracts for the pharmaceutical and nutraseutical industries. It is also important to point out that for the first time since the company's inception it has stabilized its operating costs and with its additional growth from Wellness Managed Services and the launch of Hemp Compounds that should all add to our bottom line." Quote stated by Michael Llamas, President of Medical Marijuana Inc.

DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to introduce a 4th cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.

Cannabis Science has received images and documented information from this 4th patient who has basal cell carcinoma on his left nostril. The patient is enrolled in a photographic mole-mapping program at the University of Colorado Hospital and is examined annually. The last time he was examined was in October of 2011, where his doctors found a small bump on his left nostril that was less and 1/8" in diameter, and believed it to be basal cell carcinoma. At that time it was too early to be certain if it was in-fact basal cell carcinoma.

LOS ANGELES, Feb. 1, 2012 /PRNewswire/ -- BG Medical Technologies, Inc. (OTC: RIGH) has positioned itself as a publicly-traded technology leader in medical cannabis and would like to take the time to discuss its 2012 fiscal growth strategy for shareholders and media interests.

The global vision of BG Medical is to empower individuals to be fully responsible for their personal wellness. This is accomplished through the combination of technology and media developments in three primary divisions: laboratory analysis, business support tools, and data services. The company's operational strategy is comprised of a wide variety of herbal and nutraceutical programs.

BG Medical recognizes the medical marijuana industry as an under-developed technology market capable of supporting high-yield growth. The strong social involvement of cannabis patients also serves as an optimum market for BG Medical to introduce Internet-based wellness programs. BG Medical has seized this opportunity and is best known for its popular portal for medical cannabis treatment, BudGenius.com, a provider of safety and potency testing services. Currently less than 10% of all medical cannabis consumed worldwide is laboratory tested. BG Medical estimates that cannabis testing services currently represent a $50M market. Cannabis-related advertising is estimated to grow beyond $150M in 2013. Market surveys have stated that the USA cannabis industry is expected to grow 400% by 2016.

DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce new remarkable photographic updates of the 3rd cancer patient, with treatment-resistant squamous cell carcinoma on his head.

Cannabis Science has been working with a number of self-medicated skin cancer patients, who are using cannabis-based extracts. Today Cannabis Science receives the latest photographs for the 3rd self-administering cancer patient, mentioned in the previous news release dated, January 11, 2012. The treatment process is ongoing, but the results have been visually dramatic, the cannabis extracts have drastically shrunk some tumors and others are gone.

Federal Judge Bolton dismisses all of Arizona Governor Jan Brewer's legal claims in case # 2:11 - cv-01072-SRB.

PHOENIX, Jan. 9, 2012 /PRNewswire/ -- Altitude Organic Corporation (ERBB:OTC:Pink) is pleased to announce that U.S. District Judge Susan R. Bolton has thrown out the lawsuit that has currently been blocking the Arizona medical marijuana dispensary program from proceeding. Judge Bolton made a number of comments upon dismissing the case including a comment referencing the plaintiff's complete absence of any evidence that in 16 other medical marijuana states no state employee has ever been targeted by the federal government for implementing any, "state medical marijuana licensing scheme." The court filing may be viewed in its entirety here:

http://www.acluaz.org/sites/default/files/documents/Medical%20Marijuana%...